{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chilblains/diagnosis/differential-diagnosis/","result":{"pageContext":{"chapter":{"id":"3db0f33f-97a0-5db2-83b8-ca9bb0e25bdc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis","depth":2,"htmlHeader":"<!-- begin field 281229fd-a13e-45b2-8fbd-90de13498487 --><h2>What else might it be?</h2><!-- end field 281229fd-a13e-45b2-8fbd-90de13498487 -->","summary":"","htmlStringContent":"<!-- begin item 85b61534-8f26-4be6-a9b3-cc7cba8e8e83 --><!-- begin field a8bb5d50-883a-47cc-b51d-7d1afd1f1718 --><p>The differential diagnosis of chilblains is broad and depends on the stage of the disease at presentation as well as the appearance and location of the lesions. Conditions that may present with a similar clinical picture to chilblains include:</p><ul><li><strong>Connective tissue disorders</strong> in particular lupus erythematosus and sarcoidosis (lupus pernio).<ul><li>Chilblain lupus erythematosus is a form of cutaneous lupus that presents with similar clinical features to idiopathic chilblains. Up to 20% of people with chilblain lupus develop systemic lupus erythematosus.</li></ul></li><li><strong>Haematological conditions</strong><ul><li>Cyanotic swelling of acral digital skin (often involving the toes) has been reported in people with haematological malignancy such as myelodysplastic syndrome and chronic myelomonocytic leukaemia.</li><li>Cryoglobinaemia — cryoglobulins are immunoglobulins that reversibly precipitate or gel in the cold leading to occlusion syndromes. This may present as necrotic or purpuric lesions on acral skin which have been triggered by cold exposure.</li></ul></li><li><strong>Raynaud's phenomenon</strong><ul><li>Characteristic paroxysmal and biphasic white, and later blue discolouration, after exposure to cold.</li><li>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/raynauds-phenomenon/\">Raynaud&#39;s phenomenon</a>.</li></ul></li><li><strong>Acrocyanosis</strong><ul><li>Persistent painless cyanotic or erythrocyanotic mottled duskiness of the hands (less commonly the feet and face) in the presence of normal peripheral pulses.</li></ul></li><li><strong>Cold contact urticaria</strong><ul><li>Itching and wealing of the skin within minutes of cold exposure lasting up to 1 hour.</li></ul></li><li><strong>Frostbite</strong><ul><li>Superficial frostbite (skin and subcutis) presents with erythema and initial pain followed by a sense of warmth — affected skin becomes waxy and white.</li><li>Deep frostbite (extends to subcutaneous tissues and may involve nerves, major vessels, muscle and bone) can result in joint immobility and paralysis.</li></ul></li><li><strong>Cold panniculitis</strong><ul><li>Panniculitis (inflammation of the subcutaneous fat) caused by cold exposure.</li><li>Infants are particularly susceptible to cold panniculitis but it may also occur in adults, typically obese females.</li></ul></li><li><strong>Livedo reticularis</strong><ul><li>Mottled, cyanotic discolouration of the skin with a characteristic network pattern — accentuated by cold.</li></ul></li><li><strong>Vascular or neuropathic conditions</strong><ul><li>Peripheral vascular disease, diabetes mellitus (diabetic foot), and vasculitis may present with skin changes similar to chilblains.</li></ul></li><li><strong>Granuloma annulare</strong><ul><li>Typically presents as annular indurated papules and/or plaques on the extremities which slowly enlarge before eventually flattening and fading over months or years.</li></ul></li></ul><!-- end field a8bb5d50-883a-47cc-b51d-7d1afd1f1718 --><!-- end item 85b61534-8f26-4be6-a9b3-cc7cba8e8e83 -->","topic":{"id":"98f988ea-4ee8-52e9-8212-438a79499f92","topicId":"17adddaf-c9b6-4278-9b49-932d14f56439","topicName":"Chilblains","slug":"chilblains","lastRevised":"Last revised in June 2018","chapters":[{"id":"541e07aa-8e84-55e1-817f-8d101eeb46fd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6b34a51-a690-5858-9a53-0dc5d5b0e608","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5f3bae74-0385-5bf1-b250-9e74f16cfe18","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4ae9419d-bc20-56ba-91a1-0420a339c087","slug":"changes","fullItemName":"Changes"},{"id":"e57dda70-8cbd-58d2-a2fb-8901c08e6853","slug":"update","fullItemName":"Update"}]},{"id":"ddec423e-57a6-54df-ba06-4014b41b839c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9315120c-762a-5273-867b-759b5537e4b8","slug":"goals","fullItemName":"Goals"},{"id":"666bca6f-0132-53bc-95cc-27fcbd0b4a96","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8b7e8a8e-c9dd-5555-8409-dfea005ea395","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fa795717-6d81-577e-b792-90e487b3895c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bff6f393-7347-51fa-8d46-95b80a272b9e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7da4aff5-e153-5f3f-bc51-0a943110c08d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1cc6d520-d1d7-5bcd-9d7c-b1352c82d453","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bba6260f-6b68-52b5-88c0-17f3ba449705","slug":"definition","fullItemName":"Definition"},{"id":"f4b6f42f-60f1-56db-9cc2-c9d377ec6c5a","slug":"causes","fullItemName":"Causes"},{"id":"adb617b9-5304-53c4-8f1f-6aaec8a9c35b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16008222-9ac8-5d8e-9380-55d21f8ca4d9","slug":"complications","fullItemName":"Complications"},{"id":"16a3612e-723d-580a-a4c7-157274078ba8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4c9a7bb6-deca-5726-8c77-5c4cc1bfa2a1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"468b6d0a-7e5f-59c0-affa-b0ee0c6eec91","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"08c8ac64-d612-5dfe-9926-2d0dfbc02f14","slug":"assessment","fullItemName":"Assessment"},{"id":"3db0f33f-97a0-5db2-83b8-ca9bb0e25bdc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ae9e38d9-23ba-50f8-8fd8-949711f14be6","fullItemName":"Management","slug":"management","subChapters":[{"id":"757e5e29-3beb-57b4-b55c-3050dd84bdc8","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"7f12498b-880e-5fca-908a-0c9547ba0d60","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b6be7c9c-cf67-5a2d-abb4-b8edc8d404e9","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"c98234ab-a54f-5b11-bd3d-ddc791a382d6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c4fbb70-40dc-5931-9e8e-6d8fdcd80db4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a6193060-7713-5e53-9336-66e3cb961a3a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c1d12d25-39b2-5827-a25e-dcf5536bf470","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"435de6c9-1336-5c37-8c94-8ab2ee7f2adb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"cc4fe9b8-3554-5630-88cd-6dfee9d06235","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2d1b809a-3a66-5daa-a184-7cdfb748fe77","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d01450d0-bab3-5fff-9ec6-40623a484024","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4c9a7bb6-deca-5726-8c77-5c4cc1bfa2a1","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"d0f418d7-a067-55ff-affb-04fbd565c227","slug":"basis-for-recommendation-4b1","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 9348ad30-d577-435a-8010-5ba5c2c7869e --><h3>Basis for recommendation</h3><!-- end field 9348ad30-d577-435a-8010-5ba5c2c7869e -->","summary":null,"htmlStringContent":"<!-- begin item 4b128c1c-42cf-4ab2-9041-2df81b93d103 --><!-- begin field 3fa3d00b-57d9-4539-bb8d-c83c43d5aac8 --><p>The information on the differential diagnosis of chilblains is based on the clinical guideline <em>Perniosis (syn. Chilblains)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">PCDS, 2015</a>] and expert opinion in Rook’s textbook of dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Bashir, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Guadagni, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Souwer, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Cappel, 2014</a>].</p><!-- end field 3fa3d00b-57d9-4539-bb8d-c83c43d5aac8 --><!-- end item 4b128c1c-42cf-4ab2-9041-2df81b93d103 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}